Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Stabilization of vision loss would be a big deal as cone-and rod cells are about the only cells the human body does not regenerate. I have Retinitis Pigmentosa myself, a mitochondrial disease and I'm hopeful that one day, Anavex's drug will stop the deterioriation of the retina.
Listen carefully at 17:43
wink wink :)
On slide 38 of the Anavex Noble conference presentation, Catalyst in 2017 last bullet:
"Complement current pipeline through in-licensing - ongoing"
Also, Dr. Missling litterally says at 7:53 "...with Biogen, we now work together on the Multiple Sclerosis indication".
Looks like Anavex is progressing fast towards a deal of some sort.
Send them the Noble research report, maybe they'll learn something.
The fact that this support group didn't even know about Anavex tells me they don't do their homework.
No news is good news?
On 'The Deal' discussion panel, Dr. Missling was talking about streamlining FDA and he was optimistic that it could bring approval process time down from 5-6 years to 2-3 years.
And Dr. Vamvakides sits back and gets 6% of Anavex's profits. He would soon be one of the richest Greeks on Earth.
Here's an interesting take on gap fills:
http://bevjackson.blogspot.com.es/2013/04/the-myth-of-stocks-filling-gap.html
Thanks wildcard. It looks like there are other forces at play this time around. Don't know what to make of it, but maybe it bodes well.
At least we have multiple videos to back up the positive results. Where are your NTRP videos?
I predict a close at $4.99. Seen it so many times with ADXS.
Make that sticky instead of that random georgjjl post.
They know, they know. Missling has nothing to do with their ignorance, he is just doing his job.
Maybe that's the reason the U.S. media outlets deliberately do not mention Anavex. Looks like they don't want others to know about AVXL so that certain people can load up quietly while the price is low. Take this article from Taylor Cox yesterday on Benzinga. Every Alzheimer's player is mentioned minus......Anavex. Suspicious.
http://m.benzinga.com/article/9061803
Your $2 low is a bit far fetched at this point in time (3 trials running soon) but I can live with your $10 price target for the end of the year.
Regards,
An unsophisticated investor.
Shocking but not shocking. More in the line of expectations.
It would be naive to think that they would let the Stock of the Century in the hands of 80% retail.
I like your thinking. Welcome to the board :)
Bye bye stop-losses.
Yep, old news.
Maybe someone can educate this lady on her Twitter.
I think you are remarkably bright for someone with 'diminished analytical skills'. Thanks for your efforts again.
Because Avanex is into fiber optic-based products.
I think I just saw an elephant put its leg in the pond.
Thomas Price was sworn in last week as the Secretary of Department of Health and Human Services.
Thanks wildcard. Much appreciated.
You and Tom being skilled chartists, could you maybe include the Stock Borrow/Loan (SBL) ratio, as Wildcard beautifully plotted in a graph yesterday, in your Technical Analysis? Would be nice to see if short attacks are being prepared as the days and weeks go by.
Even AF is burying the amyloid beta hypothesis now.
Not good for Merck, good for Anavex :)
http://www.marketwatch.com/story/merck-shares-slip-after-hours-as-alzheimers-study-halted-2017-02-14?link=MW_latest_news
And rising as we speak...
Double bottom at $5.90 in for today?
Yep MM's trying to steal shares from retail by taking out stop-losses.
I don't believe this rally is in anticipation of some Cures Act conference. It's more organic.
Hey Falconer, this study was just released yesterday. You may find it interesting as it hits the topic.
https://www.eurekalert.org/pub_releases/2017-02/cp-nsc020717.php
Yeah, there are tons of such sites with these typical trading parameters. It's a way of clickbaiting to make people go on their site by using popular stock tickers. It's pretty useless.
Thanks for sharing.
So this means the shorts are too scared to touch this.
We did it!